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Abstract
Purpose To evaluate the pharmacokinetic and pharmacody-
namic effects of concomitant administration of single load-
ing doses of clopidogrel or multiple doses of clopidogrel
with multiple doses of dabigatran etexilate.
Methods This was an open-label trial in healthy male sub-
jects. In part 1 (pilot, n08) and part 3 (n012), a single dose
of clopidogrel (300 or 600 mg, respectively) was given
concomitantly with dabigatran etexilate at steady state; part
2 was a randomized, multiple-dose, crossover study with the
test treatment being clopidogrel at steady state [300 mg
loading dose on day 1, then 75 mg once daily (qd)] with
concomitant dabigatran.
Results Bioavailability was moderately increased when a
loading dose of clopidogrel (300 mg in part 1 and 600 mg
in part 3) was administered concomitantly with dabigatran
etexilate 150 mg twice daily (bid). Test/reference ratios for
AUCτ,ss were 135% (90% CI 107–169%) and 132% (90%
CI 112–156%), respectively. Steady-state dosing of clopi-
dogrel 75 mg qd and dabigatran etexilate 150 mg bid (part
2) demonstrated minor effects on dabigatran pharmacoki-
netics (AUCτ,ss ratio test/reference: 91.9%, 90% CI 78.7–
107%) or its pharmacokinetic/pharmacodynamic relation-
ships (activated partial thromboplastin time, ecarin clotting
time, thrombin time). Similarly, clopidogrel bioavailability
remained unchanged by chronic administration of dabiga-
tran etexilate (part 3: ratio test/reference for AUC0−24 was
103%; 90% CI 80.3–131%), as did its pharmacodynamic
effects on the inhibition of platelet aggregation.
Conclusions When given concomitantly, dabigatran etexi-
late and clopidogrel at clinically relevant doses did not
appear to have significant effects on the pharmacokinetic
and pharmacodynamic profiles of either agent.
Keywords Clopidogrel . Comedication . Dabigatran
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Introduction
Anticoagulants and antiplatelet drugs are among the major
therapeutic agents in the treatment of coronary artery disease
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and the treatment and prevention of arterial and venous throm-
boembolic events. Given the different mechanisms of action of
these two agents, combining them has the potential for additive
and perhaps synergistic reductions in thromboembolic events
but may also lead to increased bleeding [1, 2].
Dabigatran etexilate (Pradaxa®; Boehringer Ingelheim
Pharma GmbH & Co. KG, Ingelheim, Germany) is an oral
prodrug that is rapidly converted to dabigatran, a direct
thrombin inhibitor [3, 4]. Because of thrombin’s multiple
roles in coagulation, thrombin inhibitors not only block
fibrin formation but also attenuate further thrombin forma-
tion and platelet activation [5]. Dabigatran is subject to
conjugation with activated glucuronic acid, yielding phar-
macologically active glucuronide conjugates that comprise
about 20% of the total dabigatran in plasma [6, 7].
Dabigatran is not metabolized by hepatic cytochrome P450
(CYP) isoenzymes and does not affect the metabolism of
other drugs that utilize this system. However, the prodrug
but not dabigatran is a substrate for the efflux transporter P-
gp [8]. Clopidogrel also has been shown to have some
affinity for P-gp [9]. Platelet activation can occur via the
platelet thromboxane A2 pathway, the adenosine diphos-
phate (ADP) pathway and via phosphodiesterase.
Clopidogrel inhibits the platelet-surface ADP receptor
P2Y12, decreasing platelet activation and aggregation [10].
Clopidogrel, also a prodrug, has no intrinsic antiplatelet activ-
ity and requires hepatic CYP metabolic activation to produce
its pharmacologically active metabolite, which irreversibly
inhibits ADP receptors on platelets [10, 11]. Multiple CYP
enzymes have been implicated, although CYP2C19 and
CYP3A4 are more important in the formation of the pharma-
cologically active metabolite [12, 13]. Polymorphisms in CYP
enzymes may contribute to the high variability in responsive-
ness to clopidogrel. Studies suggest that a high loading dose of
clopidogrel may reduce intra-individual variability and en-
hance responsiveness [14–17], hence use of a clopidogrel
600 mg loading dose is widespread in clinical practice.
Concomitant use of anticoagulants and antiplatelet ther-
apy is frequent in clinical practice [1, 2]. Atrial fibrillation
patients on anticoagulant therapy for stroke prevention com-
monly have concomitant conditions such as coronary heart
disease and cerebrovascular disease, for which antiplatelet
drugs are prescribed. In these patients concerns about in-
creased bleeding risks exist [18]. Accordingly, the potential
for increased risk of bleeding when the combination of an
anticoagulant and antiplatelet drug is taken is addressed in
the label of dabigatran etexilate [8]. This study was con-
ducted to evaluate whether any pharmacokinetic (PK) and/
or pharmacodynamic (PD) interactions exist.
The objectives of this study were to evaluate (1) the PK and
PD effects of concomitant administration of multiple doses of
clopidogrel 75mg once daily (qd) (preceded by a loading dose
of clopidogrel 300 mg) with multiple doses of dabigatran
etexilate 150 mg twice daily (bid) and (2) the PK and PD
effects of concomitant administration of single loading doses
of clopidogrel (300 or 600 mg) with dabigatran etexilate
(150 mg bid). Secondary PD parameters evaluated were acti-
vated partial thromboplastin time (aPTT), ecarin clotting time
(ECT), thrombin time (TT), inhibition of platelet aggregation
as well as effects on capillary bleeding time (CBT).
Methods
Subjects
Eligible subjects were healthy males aged 18–40 years, with
a body mass index (BMI) of 18.5–29.9 kg/m2, and judged to
be healthy based on medical history, physical examination,
vital signs, 12-lead electrocardiogram (ECG) and clinical
laboratory tests. Subjects were excluded if they had any of
the following: gastrointestinal, hepatic, renal, respiratory,
cardiovascular, metabolic, immunological, or hormonal dis-
orders; trauma or surgery within the last month or planned
surgery during the trial; risk of bleeding; use of drugs that
might affect blood clotting; or use of drugs that might
influence the results of the trial (e.g., inhibitors or inducers
of P-gp, CYP3A4, CYP2C9, or CYP2C19). All eligible
subjects signed written informed consent prior to enrolment.
All subjects were genotyped for single nucleotide polymor-
phisms in the CYP2C19 and CYP2C9 genes.
Study design and treatments
This open-label drug–drug interaction trial in healthy male
subjects was conducted in a single center and included a
screening evaluation prior to the conduct of any study
procedures and an end-of-study evaluation for all subjects.
Prior to study initiation, the trial was reviewed and approved
by an independent ethics committee (Ethik-Kommission der
Landesärztekammer Baden-Württemberg in Stuttgart,
Germany) and competent authority (BfArM, Germany).
The year of approval and trial conduct was 2009. The trial
was registered as required according to German drug law.
The treatment phase was divided into three separate parts,
each with a different set of subjects. Part 1 (pilot study) was
an open-label, multiple-dose (for dabigatran etexilate) and
single-dose (for clopidogrel), fixed-sequence study. A single
dose of clopidogrel 300 mg was given in addition to dabi-
gatran etexilate 150 mg bid in steady state (Table 1). Part 2
(main study) was a randomized, open-label, multiple-dose,
crossover study, with three periods of up to 5 days separated
by washout periods of at least 14 days. The test treatment
consisted of a clopidogrel 300 mg loading dose on day 1,
followed by a 75 mg dose on day 2, then clopidogrel 75 mg
qd in combination with dabigatran etexilate 150 mg bid on
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days 3–5 (Table 1). Part 3 (main study) was an open-label,
multiple-dose (for dabigatran etexilate) and single-dose (for
clopidogrel), fixed-sequence study. A single dose of clopi-
dogrel 600 mg was given alone or in addition to dabigatran
150 mg bid at steady state (Table 1).
Although there are no reported interactions of food with
dabigatran etexilate or clopidogrel [8, 19], the morning
medication was administered with about 240 mL of water
following an overnight fast of at least 10 h, and no food was
allowed until 4 h after drug administration. According to the
Table 1 Study design
Part 1






DE 150 mg bid DE 150 mg bid DE 150 mg bid DE 150 mg qd
+ clopidogrel 300 mga
Part 2




Clopidogrel 300 mg Clopidogrel 75 mg Clopidogrel 75 mg +











- - DE 150 mg bid
(day 5: qd)
Part 3













DE 150 mg bid DE 150 mg bid DE 150 mg bid
b
DE 150 mg qd +
clopidogrel 600 mga
n=12
DE dabigatran etexilate, bid twice daily, qd once daily
a Test dabigatran pharmacokinetic parameters determined from samples taken after the co-administered doses on day 4
b Reference dabigatran pharmacokinetic parameters determined from samples taken after the morning dose on day 3
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twice-daily regimen dabigatran etexilate was similarly ad-
ministered again 12 h later. Subjects were not allowed to lie
down during the 2 h following drug administration, and
water was limited for 1 h before and after drug administra-
tion. On dosing days a light non-standardized breakfast was
given 1 h after morning drug administration. On profile
days, no food was given until 4 h after administration. No
concomitant therapy was allowed during the study, except
for prophylactic thyroid hormone replacement and for
symptomatic therapy of adverse events (AEs) in need of
treatment.
Study endpoints
The primary endpoints for PK were the maximum measured
plasma concentration of the analyte at steady state (Cmax,ss)
and the area under the concentration–time curve over one
dosing interval (0–12 h for dabigatran and 0–24 h for
clopidogrel) at steady state (AUCτ,ss) for free and total
dabigatran (free and glucuronide-conjugated) and for clopi-
dogrel and its inactive metabolite (SR26334), and the Cmax
and the AUC from 0 to 24 h (AUC0–24) of clopidogrel and
SR26334 after the 300 or 600 mg clopidogrel loading doses.
The primary endpoints for PD were area under the effect
curve of ADP-induced inhibition of platelet aggregation (IPA)
at steady state of clopidogrel over one dosing interval from 0–
24 h after dosing (AUECIPA,τ,ss); maximum percentage change
compared with baseline in ADP-induced platelet aggregation
at steady state of clopidogrel (Emax,IPA,ss); AUEC from 0 to
24 h (AUECIPA,0–24) after the loading dose of clopidogrel
600 mg; and the maximum percentage change compared with
baseline in ADP-induced platelet aggregation from 0 to 24 h
(Emax,IPA,0–24) after the loading dose of clopidogrel 600 mg.
The secondary endpoints included other PK parameters
and the effects of clopidogrel on the PD of dabigatran
assessed by ECT, aPTT, TT (including maximum effect
ratio, ERmax) as well as the CBT.
PK/PD determinations (bioanalytics)
For PK parameter evaluations, blood samples were taken for
the determination of plasma concentrations of free, noncon-
jugated dabigatran, total dabigatran (after alkaline cleavage
of conjugates), and the prodrug dabigatran etexilate, and of
clopidogrel and SR26334.
The following PD parameters were also evaluated:
– For clopidogrel, ADP-induced IPA was determined at
predefined time points.
– Capillary bleeding times were assessed (part 2 and part
3 of the study) before clopidogrel administration, 2, 4,
and 12 h after clopidogrel administration, and following
administration of dabigatran etexilate alone.
Blood samples were taken before and at specified inter-
vals up to 24 h after the morning clopidogrel dose, and
before and up to 24 h after the morning and evening dabi-
gatran etexilate dose. Timings of PK/PD sampling are
shown in Supplementary Table 1.
Blood samples (∼2.7 mL for dabigatran and ∼4.0 mL for
clopidogrel) were collected into tubes containing potassium
ethylenediaminetetraacetic acid for PK analysis. Samples
were centrifuged, and the resulting plasma samples were
separated and stored at −70°C or below.
Plasma concentrations of free, nonconjugated dabigatran;
total dabigatran (sum of free and conjugated dabigatran mea-
sured after alkaline cleavage of conjugates); the prodrug dabi-
gatran etexilate; clopidogrel; and SR26334 were determined
by validated high-performance liquid chromatography tandem
mass spectrometry (HPLC-MS/MS) at AAI Pharma
Deutschland (Neu-Ulm, Germany). The calibration curves
for free and total dabigatran covered a range from 1.00 to
400 ng/mL plasma in undiluted samples. The calibration
curves were linear over the calibration range and no interfer-
ence from endogenous compounds was observed. Maximum
imprecision and inaccuracy for quality control samples at con-
centrations of 3, 30, and 320 ng/mL were 6.62 and +5.86%,
respectively. For the prodrug, maximum imprecision and inac-
curacy were 6.63 and +2.83%, respectively.
Calibration curves for clopidogrel and SR26334 covered
concentration ranges of 0.01–10 ng/mL and 0.02–20 μg/mL,
respectively, with an inaccuracy generally below 4% and
imprecision below 9%. For blood coagulation parameters
aPTT, ECT, and TT (PD analyses), ∼3 mL of blood were
collected in sodium citrate monovettes at the time points
indicated for PK analyses. The blood samples were centri-
fuged, frozen, and stored at −20°C or below. The aPTT, ECT,
and TT parameters were analyzed on an MC10PLUS coagul-
ometer using validated methods by BiochemA, Riegel,
Germany. aPTT was measured using a kit from Roche
Diagnostics (Mannheim, Germany) according to manufac-
turer’s instructions, and the ECT assay utilized ecarin from
Pentapharm (Basel, Switzerland). Thrombin inhibition (TT),
anti-factor IIa, was measured by the Hemoclot Thrombin
Inhibitors Assay® (Hemoclot® TT #CK002K, HYPHEN
BioMed, Neuville-sur-Oise, France) according to the manu-
facturer’s instructions. The Hemoclot kit was used for the
quantitative measurement of direct thrombin inhibitors in
plasma, with a clotting method based on the inhibition of a
constant and defined concentration of thrombin.
For platelet aggregation testing, ∼9 mL of blood was
collected into a 10 mL monovette containing citrate to yield
a final concentration of 10.6 mM. Platelet-rich plasma
(PRP) was prepared by centrifugation and removed from
the red-cell sediment. Approximately 0.5 mL platelet-poor
plasma (PPP) was prepared from PRP by further centrifu-
gation. Inhibition of platelet aggregation was performed by
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light transmission aggregometry in citrated PRP, using an 8-
channel platelet aggregation profiler (PAP 8) aggregometer
(möLab, Germany). The PRP (0% light transmission) and
PPP (100% light transmission) served as reference. After
baseline adjustment, ADP in a final concentration of 20 μM
was added and aggregation recorded for 6 min. Maximum
aggregation (%) within the first 6 min after addition of ADP
was determined.
The bleeding timewas assessed by single measurements on
the forearm using the Surgicutt® Bleeding Time Device
(Product Number SUB50, International Technidyne, Edison,
NJ, USA). Using a Surgicutt device, a standardized incision of
5 mm length and 1 mm depth was made in the skin. Every
30 s, the blood flow was wicked away cautiously with filter
paper, so that the platelet plug remained intact, until the
bleeding stopped. Normal bleeding time was under 8 min.
Safety
Safety was assessed by medical examination, pulse rate,
blood pressure, ECG, clinical and laboratory parameters,
AEs, and an assessment of clinical global tolerability
(4-point scale: good, satisfactory, not satisfactory, and bad).
Statistical methods
The aim of the trial was to estimate the relative bioavail-
ability (ratio of exposure: test/reference) and its 90% confi-
dence interval (CI) regarding PK and PD parameters (as
listed below). Different test and reference treatments were
compared by applying the average bioequivalence method.
Point estimates for the test/reference ratios and the
corresponding 90% CIs were calculated using an analysis
of variance (ANOVA) based on the logarithmic scale re-
garding PK parameters (multiplicative model) and on the
original scale for PD parameters (additive model). The
ANOVA model included effects accounting for the follow-
ing sources of variation: “sequence,” “subject within se-
quence,” “period,” and “treatment” (crossover design of
part 2). The effect “subject within sequence” was considered
as random, whereas the other effects were considered as fixed.
For parts 1 and 3 “sequence” was not considered because of
the fixed sequence design. Two-sided 90% CIs for the test/
reference ratios were interpreted exploratively, and no statis-
tical hypotheses were tested in a confirmatory sense.
In pilot part 1 and main part 3, the following primary PK
and PD parameters were compared intra-individually:
– AUCτ,ss and Cmax,ss of total dabigatran
– Cmax and the AUC from 0 to 24 h (AUC0–24) of clopi-
dogrel and inactive metabolite SR26334
– AUECIPA,0–24 and Emax,IPA,0–24
In main part 2, the following primary PK or PD param-
eters were compared intra-individually:
– AUCτ,ss and Cmax,ss of total dabigatran, clopidogrel, and
inactive metabolite SR26334
– AUECIPA,τ,ss and Emax,IPA,ss (syn. to AUECIPA,0–24 and
Emax,IPA,0–24 at steady state)
AUEC and ERmax of aPTT, ECT, and TT as well as CBT,
and safety and tolerability were assessed descriptively as
secondary parameters.
For the CBT individual listings including the baseline
value, the maximum value of the post-dose measurements,
and the corresponding time of the maximum value were
provided. Frequency tables of the three categories (<10,
10–30, >30 min) for the maximum CBT values were pro-
vided (part 2 and part 3).
Sample sizes of 8 subjects in part 1 and 12 subjects in
part 3 of the trial were considered sufficient to achieve the
exploratory aims. The sample size of 24 subjects in part 2
was chosen to ensure that the estimation of ratios is precise.
The desired precision is represented by the half-width of the
90% confidence interval of the point estimate on the loga-
rithmic scale. In previous single-dose studies, intra-
individual variabilities (gCVs) ranging from about 40 to
50% were observed for PK exposure parameters. The gCV
after multiple dosing can be expected to be lower. In case of
a gCV of 35%, a 90% CI for the ratio of the test/reference
means for a PK parameter would be obtained with 95%
probability and a desired precision of 0.2231 (on the loga-
rithmic scale). For a ratio of 100%, this precision corre-
sponds to an interval of 80 to 125%.
The calculation was performed using the MOC3 routine
from commercial software nQuery Advisor [20].
Results
Study subjects (parts 1, 2, and 3)
A total of 44 healthy male volunteers entered the study and
were treated: 8 subjects in part 1, 24 in part 2, and 12 in part
3. A summary of demographic and baseline characteristics
is shown in Table 2. All subjects in the trial were white,
except for one who was of American-Indian/Alaska native
ethnic origin. Genotyping revealed that three subjects were
homozygous for the deficient *2 allele of CYP2C19, nine were
heterozygous carriers of the CYP2C19 *2 allele, four subjects
had the CYP2C19 *17 allele (leading to higher CYP2C19
activity), and two subjects carried only low-activity alleles *2
or *3 of CYP2C9, whereas 11 showed the CYP2C9*1/*2 or *1/
*3 genotype. All other subjects were genotyped as normal
(extensive) metabolizers. Forty subjects completed the trial.
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Part I
PK parameters
Maximum plasma concentrations of free and total dabigatran
were increased when clopidogrel 300 mg was coadministered
with dabigatran etexilate 150 mg compared with concentrations
observedwhen dabigatran etexilate was administered alone. The
shapes of the plasma-concentration-time curves of free and total
dabigatran and clopidogrel and SR26334 were similar with or
without coadministration of 300 mg clopidogrel. Cmax,ss in-
creased by 69% when clopidogrel 300 mg was coadministered
with dabigatran 150 mg bid. The corresponding change in
AUCτ,ss of total dabigatran was a 35% increase when clopidog-
rel 300 mg was coadministered with dabigatran 150 mg bid
(Table 3). Clopidogrel was not associated with other changes in
total dabigatran PK parameters.
AUC0–24 for clopidogrel with dabigatran etexilate 150 mg
bid was 8,580 pg·h/mL and for SR 26334 with dabigatran
etexilate 150 mg bid was 35,400 pg h/mL. Large variability
[geometric coefficient of variation (gCV)] between 171 and
258% with respect to the primary PK parameters of clopidogrel
was observed, although the variability for the major circulating
metabolite SR26334 was low (13–21% gCV).
PD parameters
Inhibition of platelet aggregation A maximum of about
50% inhibition of ADP-dependent platelet aggregation
(Emax) was observed after a single dose of clopidogrel
300 mg (part 1; data not shown).
Blood coagulation parameters (aPTT, ECT, and anti-factor
IIa) In part 1, the effect of dabigatran on these coagulation
parameters was slightly increased when a single dose of
clopidogrel 300 mg was added to steady-state dabigatran
etexilate 150 mg bid. The greatest change was seen in the
gMean AUECτ,ss of aPTT, which was increased by about
30% when dabigatran etexilate was administered with
clopidogrel.
Table 2 Demographic and other baseline characteristics
Part 1 (n08) Part 2 (n024) Part 3 (n012)
Age, years, mean ± SD (range) 28.9±4.1 (22–33) 31.5±5.5 (23–40) 32.8±5.6 (22–40)
Ethnicity, n (%)
White 8 (100.0) 24 (100.0) 11 (91.7)
American Indian/Alaska native 0 0 1 (8.3)
Weight, kg, mean±SD (range) 79.6±9.9 (69–96) 80.4±7.4 (64–91) 81.6±9.4 (68–100)
BMI, kg/m2, mean±SD (range) 24.89±2.52 (21.8–29.4) 24.92±2.32 (19.3–28.7) 26.45±1.73 (24.1–29.5)
Smokers, n (%)
Never smoked 3 (37.5) 15 (62.5) 5 (41.7)
Ex-smoker 2 (25.0) 8 (33.3) 1 (8.3)
Current smoker 3 (37.5) 1 (4.2) 6 (50.0)
Alcohol intake, n (%)
Non-drinker 4 (50.0) 13 (54.2) 1 (8.3)
Drinker, no interference 4 (50.0) 11 (45.8) 11 (91.7)
BMI Body mass index, SD standard deviation
Table 3 Part 1. Adjusted geometric means (gMean) and gMean ratios of total dabigatran pharmacokinetic parameters when dabigatran etexilate
150 mg was administered twice daily with or without a single dose of clopidogrel 300 mg
Parameter DE 150 mg + clopidogrel 300 mg DE 150 mg Ratio test/reference,
% gMean
90% Cl Intra-individual
gCV, %Test, gMean (n08) Reference, gMean
(n08)
Total dabigatran
AUCτ,ss, ng·h/mL 979 727 135 107, 169 24.4
Cmax,ss, ng/mL 184 109 169 135, 212 24.0
CL/Fss, mL/min 1920 2580 74.4
AUCτ,ss Area under the concentration–time curve of the analyte in plasma at steady state over a uniform dosing interval τ, CI confidence interval,
CL/Fss apparent clearance of analyte in plasma following extravascular administration, Cmax,ss maximum plasma concentration at steady state,
DE dabigatran etexilate, gCV geometric coefficient of variation
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Part 2
PK parameters
There was no apparent change in the shape of the plasma
concentration–time curves of dabigatran in subjects who
received dabigatran etexilate 150 mg alone or after multiple
doses of clopidogrel 75 mg qd (preceded by a loading dose
of 300 mg). Similarly, dabigatran etexilate 150 mg bid had
no influence on the shape of the plasma concentration–time
curves of clopidogrel and SR26334 after multiple doses of
clopidogrel (Supplementary Fig. 1a, b).
Repeated doses of clopidogrel had no effect on the steady-
state PK (AUCτ,ss and Cmax,ss) of free and total dabigatran, and
intra-individual variations were similar in each case.
Clopidogrel had no effect on dabigatran etexilate glucuronida-
tion. Table 4 shows the ratios and confidence intervals of the
PK parameters of dabigatran etexilate 150 mg bid when given
in combination with clopidogrel 75 mg qd (preceded by a
300 mg loading dose) versus dabigatran 150 mg alone.
The corresponding ratios and confidence intervals of the
PK parameters of clopidogrel and SR26334 with dabigatran
etexilate 150 mg bid given in combination with clopidogrel
75 mg qd (preceded by a 300 mg loading dose) versus
clopidogrel 75 mg alone showed that concomitant adminis-
tration did not alter exposure to the parent drug or the major
metabolite.
The time to Cmax (tmax,ss; 2 h) and half-life (t1/2,ss; ∼9.5 h)
were similar in subjects receiving multiple doses of dabiga-
tran etexilate 150 mg alone or in combination with repeated
oral doses of clopidogrel 75 mg (300 mg loading dose).
PD parameters
Inhibition of platelet aggregation Coadministration of dabi-
gatran etexilate 150 mg did not alter the maximum ADP-
dependent platelet aggregation achieved after a single dose of
clopidogrel 300 mg (Fig. 1). Following repeated doses of clo-
pidogrel 75 mg (preceded by 300 mg loading dose), the Emax,ss
Table 4 Part 2. Adjusted geometric means (gMean) and gMean ratios
of total dabigatran, clopidogrel, and SR26334 multiple dose pharma-
cokinetic parameters when dabigatran etexilate (DE) 150 mg twice
daily (bid) was administered in combination with clopidogrel 75 mg
once daily (qd) (preceded by a 300 mg loading dose) versus dabigatran
etexilate 150 mg bid alone or clopidogrel 75 mg qd alone
Parameter Clopidogrel 75 mg qd + 
DE 150 mg bid
Test treatment, gMean
(n=21)







90% Cl Intra-individual 
gCV (%)
Total dabigatran










Clopidogrel 75 mg qd + 
DE 150 mg bid
Test treatment, gMean
(n=21)











a 1400b 115 104, 127 13.8
Cmax,ss, pg/mL 677 625 108 87.3, 134 41.2
SR26334
AUCτ,ss, ng·h/mL 8807 8008 110 104, 117 11.1
Cmax,ss, ng/mL 2760 2689 103 90.5, 116 23.8
AUCτ,ss Area under the concentration–time curve of the analyte in plasma at steady state over a uniform dosing interval τ, CI confidence interval,
CL/Fss apparent clearance of analyte in plasma following extravascular administration, Cmax,ss maximum plasma concentration at steady state,
gCV geometric coefficient of variation
a n014
b n017
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of IPAwas approximately 50%with or without coadministration
of multiple doses of dabigatran etexilate 150 mg bid (part 2).
Analyses revealed modestly lower AUECτ,ss and Emax,ss
of IPA with regard to the comparison of the combined
treatment with multiple doses of clopidogrel 75 mg qd
(preceded by a loading dose of 300 mg) and multiple doses
of dabigatran etexilate 150 mg versus treatment with multi-
ple doses of clopidogrel alone (Table 6).
Blood coagulation parameters (aPTT, ECT and anti-factor
IIa) In part 2, AUECIPA,τ,ss and ERmax,ss of TT, ECT, and
aPTT were not altered after concomitant administration of
repeated doses of clopidogrel 75mg qd (300mg loading dose)
and multiple doses of dabigatran etexilate 150 mg bid. A trend
towards a higher IPA activity was observed in subjects with
the CYP2C19*17 allele. CYP2C19*17 is associated with
faster metabolism of clopidogrel to its pharmacologically
active metabolite [21]. CYP2C9 polymorphism was not asso-
ciated with differences in maximum IPA activities.
In evaluation of PK/PD, a linear relationship between
plasma concentration and coagulation prolongation was ob-
served for both TT and ECT, whereas the relationship was
nonlinear between plasma concentration and aPTT. No ef-
fect of clopidogrel on the PK/PD relationship was found
when dabigatran etexilate was given alone or in combina-
tion with clopidogrel (Fig. 2).
Capillary bleeding time In part 2, the maximum CBT was
prolonged by any treatment that included clopidogrel.
However, no difference could be observed between clopidog-
rel monotherapy and clopidogrel+dabigatran etexilate combi-
nation therapy. Dabigatran alone did not prolong the CBT.
Part 3
PK parameters
The maximum plasma concentrations of free and total dabi-
gatran were increased when clopidogrel 600 mg was coad-
ministered with dabigatran etexilate 150 mg bid at steady
state. However, the general shape of the plasma concentra-
tion–time profiles of free and total dabigatran was not al-
tered. There was no detectable difference between the
plasma concentration–time profiles of clopidogrel or
SR26334 when clopidogrel 600 mg was administered alone
or with dabigatran etexilate 150 mg bid. Clopidogrel had no
effect on dabigatran glucuronidation (Supplementary
Fig. 2a, b).
Calculation of geometric mean (gMean) ratios
showed that the bioavailability (AUCτ,ss) of total dabi-
gatran was increased by 32% when dabigatran etexilate
150 mg bid was administered together with a single
dose of clopidogrel 600 mg. The maximum plasma
concentration (Cmax,ss) of total dabigatran was similarly
affected, increasing by 43% (Table 5). The effect of
clopidogrel on the exposure of free dabigatran was
similar to that observed with total dabigatran. The
AUC0–24 and Cmax for clopidogrel and SR26334 after
clopidogrel 600 mg alone were only minimally affected
by coadministration with dabigatran 150 mg bid at
steady state (Table 5).
PD parameters
Inhibition of platelet aggregation A maximum of about
60% inhibition of ADP-dependent platelet aggregation
(Emax) was observed after a single dose of clopidogrel
600 mg (part 3; Table 6). The AUECτ,ss in participants
taking multiple doses of dabigatran etexilate 150 mg con-
comitantly with a single dose of clopidogrel 600 mg was
Fig. 1a, b Part 2. Effect of comedication with dabigatran on inhibition
of platelet aggregation (IPA) by clopidogrel. Comparison between
clopidogrel monotherapy and clopidogrel + dabigatran of individual
and geometric mean (gMean) AUECτ,ss (a) and Emax,ss values of IPA
(b). AUECτ,ss Area under the effect curve of inhibition of platelet
aggregation (at steady state), Emax,ss maximum percentage change
(compared with baseline) in adenosine triphosphate-induced platelet
aggregation of clopidogrel (at steady state)
334 Eur J Clin Pharmacol (2013) 69:327–339
lower than that of the treatment group taking a single dose of
clopidogrel 600 mg (1,179 versus 1,264, respectively; 90%
CI –293 to 124) (Table 6).
Blood coagulation parameters (aPTT, ECT, and anti-factor
IIa) In part 3, the dabigatran-related effect on TT, ECT,
and aPTT after administration of dabigatran etexilate
150 mg bid was slightly increased when a single dose
of clopidogrel 600 mg was coadministered. The greatest
change (approximately 36.5%) was seen in the AUECτ,ss of
aPTT, when dabigatran etexilate was administered with
clopidogrel.
Capillary bleeding time In part 3, the coadministration of
dabigatran etexilate 150 mg bid with clopidogrel 600 mg did
not increase the CBT compared with a single dose of clopi-
dogrel 600 mg given alone.
Safety (parts 1, 2, and 3)
All AEs were of mild or moderate intensity. All events
resolved by the end of the trial, except for an ongoing
condition of hemorrhoids in one subject in part 2. There
were no deaths, serious AEs, or AEs of severe intensity.
Fig. 2a–c Part 2. Effect of
clopidogrel on ecarin clotting
time (ECT) ratio (a), activated
partial thromboplastin time
(aPTT) ratio (b), and TT
(anti-factor IIa) ratio (c) after
multiple oral administrations of
dabigatran etexilate 150 mg
twice daily with or without
coadministration of repeated
doses of 75 mg clopidogrel
once daily (300 mg loading
dose)
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The most frequently reported AEs in all study parts were
nervous system disorders, specifically headache. Four sub-
jects reported AEs considered related to the study drugs.
These were hematoma (part 2: one subject, clopidogrel
75 mg; one subject, during washout after the first treatment
period), hematuria (part 2: one subject, clopidogrel+dabiga-
tran etexilate), and rash, i.e., exanthema on both hands (part
3: one subject, dabigatran etexilate+clopidogrel).
Overall, four subjects discontinued treatment premature-
ly. In part 2, two subjects discontinued treatment because of
an AE: one for moderate hemorrhoids after receiving dabi-
gatran etexilate alone (considered not to be drug related),
and one for moderate hematuria while receiving clopidogrel
+dabigatran etexilate. A third subject withdrew his consent
after receiving clopidogrel alone. In part 3, one subject
withdrew his consent after receiving clopidogrel alone.
Vital signs, ECG, and safety laboratory assessments did
not indicate any relevant, consistent, or treatment-related
untoward reactions. Global clinical tolerability was good
in all subjects, except in one subject during treatment with
clopidogrel+dabigatran. This subject, who reported global
tolerability as “not satisfactory,” discontinued the trial be-
cause of an AE (moderate hematuria).
Discussion
Given the different mechanisms of action of anticoagulants and
antiplatelet drugs, combining these agents has the potential to
reduce thromboembolic events and their consequences, al-
though with the likelihood of an increased risk of bleeding [1,
2]. Furthermore, if any drug–drug interactions between the
selected anticoagulant and antiplatelet drugs are present, the
bleeding risk could be substantially increased. Our study shows
that after multiple dosing of clopidogrel 75 mg qd (preceded by
a loading dose of 300mg) plus dabigatran etexilate 150mg bid,
exposure to free and total (free and glucuronide-conjugated)
dabigatran remained essentially unchanged compared with
Table 5 Part 3. Adjusted geometric means (gMean) and gMean ratios
of total dabigatran, clopidogrel, and SR26334 pharmacokinetic param-
eters when dabigatran etexilate (DE) 150 mg twice daily (bid) was
administered in combination with a single dose of clopidogrel 600 mg
versus dabigatran 150 mg bid alone or clopidogrel 600 mg alone

















































AUC0–24, ng·h/mL 82.5 84.3 97.8 83.5, 115 20.8
Cmax, ng/mL 18505 21604 85.7 68.3, 107 30.4
AUCτ,ss Area under the concentration–time curve of the analyte in plasma at steady state over a uniform dosing interval τ, CI confidence interval,
Cmax,ss maximum plasma concentration at steady state, CL/Fss apparent clearance of analyte in plasma following extravascular administration,
gCV geometric coefficient of variation
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dabigatran etexilate monotherapy. Concomitant intake of
clopidogrel did not affect dabigatran glucuronidation,
and no or only minimal effects of dabigatran on the
PK of clopidogrel or its inactive metabolite (SR26334),
or on the inhibition of platelet aggregation induced by the
active metabolite of clopidogrel were observed.
Clopidogrel in this therapeutic regimen (a 300 mg loading
dose followed by 75 mg qd) had only minimal effects on the
coagulation markers aPTT, ECT, and TT; the latter two are
closely related to thrombin inhibition. Accordingly, the effect
of dabigatran and the PK/PD relationship were essentially the
same when dabigatran etexilate was given with or without
concomitant clopidogrel. A high loading dose of clopidogrel
600 mg also had no effect on the thrombin-related coagulation
markers.
Clopidogrel inhibits the platelet-surface ADP receptor
P2Y12, decreasing platelet activation and aggregation
processes [10]. Dabigatran did not influence the inhibition of
ADP-dependent platelet aggregation by clopidogrel.
Furthermore, dabigatran alone did not prolong CBT, a mea-
sure to assess platelet-driven coagulation [22, 23]. Maximum
CBT was clearly prolonged by any treatment regimen that
included clopidogrel compared with dabigatran monotherapy.
However, there was no difference in CBT between clopidog-
rel given alone or in combination with dabigatran etexilate. In
atrial fibrillation patients, however, from the RE-LY trial,
concomitant intake of clopidogrel and dabigatran etexilate
led to an increased rate of major and any bleeding [24]. In a
phase I trial, the first oral direct thrombin inhibitor, ximelaga-
tran, in combination with acetylsalicylic acid (ASA) further
prolonged CBT by about 40% compared with ASA alone
[25]. Bleeding time with the combination rivaroxaban and
clopidogrel was significantly prolonged in four subjects, com-
pared with either drug alone, which increased the overall least
square means to 3.77 (90% CI 2.82–4.73) times baseline with
the combination, compared with 1.13 times baseline (90% CI
0.17–2.09) with rivaroxaban and 1.96 times baseline (90% CI
0.10– 2.91) with clopidogrel [26]. The results with dabigatran
observed in this study seem to some extent different from
previously observed data with other oral anticoagulants such
as ximelagatran and rivaroxaban.
Ahighloadingdoseofclopidogrel600mgwasassociatedwith
anincrease(32%)in thebioavailabilityofdabigatran.Exposure to
clopidogrel and SR26334 was similar when clopidogrel was
administered alone or withmultiple doses of dabigatran etexilate
150mgbid.TheeffluxtransporterP-gpinthegastrointestinal tract
can directly limit oral drug absorption [27, 28]; dabigatran etex-
ilate, but not dabigatran, is a substrate for P-gp [8, 29].
Concomitant administration of strong P-gp inhibitors, including
quinidine, amiodarone, verapamil, ketoconazole, and clarithro-
mycin, raises dabigatran serum concentrations [8, 29, 30].
Clopidogrel also has been shown to be a substrate of P-gp [9].
Clopidogrel absorption, and thereby formation of its active me-
tabolite, is diminished by P-gp-mediated efflux [9]. A high
Table 6 Parts 2 and 3. Means (original scale) and differences in inhibition of ADP-induced platelet aggregation by clopidogrel in combination with
dabigatran etexilate (DE) and alone
Parameter
Part 2
Clopidogrel 75 mg qd 
+ DE 150 mg bid
Test treatment 







n Mean n Mean
AUECIPA, τ,ss, 
%·h
21 456 21 496 –39.7 (–8.0%) –96.5 to 17.2 20.3
Emax, ss 21 55.1 23 58.8 –3.71 (–6.3%) –12.9 to 5.49 29.0
Parameter
Part 3
Clopidogrel 600 mg + 









n Mean n Mean
AUEC0–24, %·h 11 1179 12 1264 –84.6 (–6.7%) –293 to 124 21.6
Emax 11 66.8 12 66.0 0.826 (1.3%) –10.8 to 12.5 23.4
AUEC0–24 Area under the effect curve of inhibition of platelet aggregation after the loading dose of 600 mg clopidogrel from drug administration
until 24 h thereafter (at steady state), AUECτ,ss area under the effect curve of inhibition of platelet aggregation (at steady state), bid twice daily,
CI confidence interval, Emax maximum percentage change (compared with baseline) in ADP-induced platelet aggregation of clopidogrel (Emax,ss, at
steady state), qd once daily
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loading dose of clopidogrel (either 300 or 600mg)may have the
potential to competitively inhibit intestinal P-gp, causing an in-
crease indabigatranbioavailability.Ahigh, 600mg, loadingdose
of clopidogrel is widely used in clinical practice, especially in
acute settings, to reduce intra-individual variability and enhance
responsiveness [14–17]. However, this clopidogrel loading dose
is given for only 1 day. This transient increase in dabigatran
exposure for a single day by about 30% should be taken into
consideration particularly in vulnerable patients at high risk of
bleeding. However, it remains to be determined whether this
effect, which is only observed for the first day of a combination
treatment, is likely to have any clinical impact at all.
Unlike dabigatran, which is not metabolized via CYP
isoenzymes, clopidogrel requires hepatic CYP metabolic
activation to produce its pharmacologically active metabo-
lite [10, 11]. In addition to CYP3A4, CYP2C19 is particu-
larly important relative to other CYP enzymes in the
formation of the active metabolite of clopidogrel [12, 13].
As neither dabigatran nor its prodrug is an inhibitor of any
CYP, dabigatran comedication should not diminish the ther-
apeutic efficiency of clopidogrel. In accordance with pub-
lished data [21], subjects carrying the ultrarapid metabolizer
allele CYP2C19*17 had a trend to more efficient inhibition
of ADP-dependent platelet aggregation. However, in gener-
al the CYP2C19 genotype did not influence PK and PD after
comedication with dabigatran etexilate.
Concomitant administration of dabigatran and clopidog-
rel did not reveal any unexpected safety findings in the
healthy male subjects included in this clinical trial. All
AEs observed were of mild to moderate intensity, none were
serious, and all had resolved by the end of the study, with
the exception of ongoing hemorrhoids in one subject.
Reported AEs, including hematoma, hematuria, and rash,
were consistent with the labelling of dabigatran and clopi-
dogrel and were not unexpected, even in healthy volunteers.
Three bleeding events were potentially related to drug
effects on coagulation: two cases of moderate hematoma
(one subject given clopidogrel alone; one subject receiving
clopidogrel+dabigatran) and one case of moderate hematu-
ria (subject received clopidogrel+dabigatran and subse-
quently discontinued treatment). However, there was no
correlation between the individuals’ PK data and these
bleeding events. Although these results are not conclusive,
dabigatran etexilate in this study did not seem to cause any
safety issues, whether given alone or in combination with
clopidogrel.
The study was designed as a phase I study in healthy
volunteers and aimed to clarify any PK/PD interaction be-
tween clopidogrel and dabigatran etexilate. This type of
study does not allow any conclusions to be drawn with
respect to the clinical effects of long-term use of the com-
bination in atrial fibrillation patients. However, dabigatran
etexilate was administered at the therapeutic dose of 150 mg
bid, and clopidogrel was administered at dosages used in
clinical practice. The designs of the pilot and two main parts
of the study were purposefully chosen. The pilot study (part
1) had a fixed-sequence design (multiple doses of dabiga-
tran 150 mg followed by a single dose of clopidogrel) for
safety reasons. In the main study, the crossover design was
used as is usually done for drug–drug interaction studies due
to its efficiency, i.e., the comparison between treatments
based on a comparison within subjects rather than between
subjects (part 2). A washout period of 14 days was consid-
ered to be sufficient to separate the three treatments, based
on the half-life of dabigatran (8–10 h and 14–17 h with
single- and multiple-dose administrations, respectively [7]).
The combination of dabigatran with a high clopidogrel dose
(600 mg) warranted a fixed-sequence design (one drug alone
followed by the combination) for safety reasons (part 3).
In summary, steady-state dosing of clopidogrel 75 mg qd
(following a 300 mg loading dose) and dabigatran etexilate
150mg bid demonstrated no effect on dabigatran PK or PD, or
its PK/PD relationships (aPTT, ECT, or TT). Similarly, the PK
of clopidogrel and its PD effects on the inhibition of platelet
aggregation were unchanged by chronic administration of
dabigatran etexilate. There may be modest but very transient
effects on dabigatran PK (30–35% increase in AUC) when a
loading dose of clopidogrel (300 or 600 mg) is administered,
with no impact on the PK or PD of clopidogrel.
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